271 related articles for article (PubMed ID: 8633815)
1. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
[TBL] [Abstract][Full Text] [Related]
4. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
[TBL] [Abstract][Full Text] [Related]
7. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Ungsedhapand C; Kroon ED; Suwanagool S; Ruxrungtham K; Yimsuan N; Sonjai A; Ubolyam S; Buranapraditkun S; Tiengrim S; Pakker N; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):116-23. PubMed ID: 11404532
[TBL] [Abstract][Full Text] [Related]
9. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
Katzenstein DA; Hughes MD; Albrecht M; Liou SH; Murphy R; Balfour H; Para M; Hammer S;
AIDS Res Hum Retroviruses; 2001 Feb; 17(3):203-10. PubMed ID: 11177402
[TBL] [Abstract][Full Text] [Related]
10. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
[TBL] [Abstract][Full Text] [Related]
11. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Katzenstein DA; Hammer SM; Hughes MD; Gundacker H; Jackson JB; Fiscus S; Rasheed S; Elbeik T; Reichman R; Japour A; Merigan TC; Hirsch MS
N Engl J Med; 1996 Oct; 335(15):1091-8. PubMed ID: 8813039
[TBL] [Abstract][Full Text] [Related]
12. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Friedland GH; Pollard R; Griffith B; Hughes M; Morse G; Bassett R; Freimuth W; Demeter L; Connick E; Nevin T; Hirsch M; Fischl M
J Acquir Immune Defic Syndr; 1999 Aug; 21(4):281-92. PubMed ID: 10428106
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Lallemant M; Ngo-Giang-Huong N; Jourdain G; Traisaithit P; Cressey TR; Collins IJ; Jarupanich T; Sukhumanant T; Achalapong J; Sabsanong P; Chotivanich N; Winiyakul N; Ariyadej S; Kanjanasing A; Ratanakosol J; Hemvuttiphan J; Kengsakul K; Wannapira W; Sittipiyasakul V; Pornkitprasarn W; Liampongsabuddhi P; McIntosh K; Van Dyke RB; Frenkel LM; Koetsawang S; Le Coeur S; Kanchana S;
Clin Infect Dis; 2010 Mar; 50(6):898-908. PubMed ID: 20158398
[TBL] [Abstract][Full Text] [Related]
15. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
16. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
Collier AC; Coombs RW; Fischl MA; Skolnik PR; Northfelt D; Boutin P; Hooper CJ; Kaplan LD; Volberding PA; Davis LG; Henrard DR; Weller S; Corey L
Ann Intern Med; 1993 Oct; 119(8):786-93. PubMed ID: 8379600
[TBL] [Abstract][Full Text] [Related]
19. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
20. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
